Orion Oyj (0M2O.L)
| Previous Close | 45.91 |
| Open | 45.89 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 45.60 - 45.89 |
| 52 Week Range | 36.03 - 55.14 |
| Volume | |
| Avg. Volume | 105,676 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Inside information: Orion upgrades full-year outlook for 2024
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion and MSD (Merck & Co., Inc., Rahway, NJ, USA) have exercised the option to convert the co-development and co-commercialisation agreement with MSD regarding opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and
- GlobeNewswire
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer Orion Corporation (“Orion”) and MSD (Merck & Co., Inc., Rahway, NJ, USA) today announced that notice has been provided of the mutual exercise of an option to convert the companies’ on
- GlobeNewswire
Orion is developing the Finnish life science industry in a unique collaboration project
ORION CORPORATION PRESS RELEASE 03 June 2024 at 09.30 EEST Orion is developing the Finnish life science industry in a unique collaboration project Orion is participating in a project led by the University of Turku for which Business Finland recently granted 11.7M€ funding. The project seeks to enhance advanced pharmaceutical and life science manufacturing in Finland. The LifeFactFuture project combines world-class-excellence of Finnish life science companies, technology companies, and academic r
